If you are not happy with the results below please do another search
The FDA nod “represents an important first step that will one day allow our technology to help many people,” Neuralink said in a tweet. It did not elaborate on the aims of the study, saying only that it was not recruiting yet and more details would be available soon.
Today AstraZeneca announced that a combination of its cancer drugs Imfinzi and Lynparza when added to platinum-based chemotherapy showed positive results in a late-stage trial in patients with advanced or recurrent endometrial cancer.
The Massachusetts-based biopharma became the second company this week to drop its amyotrophic lateral sclerosis hopeful after it failed to elicit significant improvement compared with placebo.
Justin Chase, executive vice president of media, EVERSANA INTOUCH discusses trends in social media how healthcare communicators can leverage different platforms to build stronger relationships with patients and HCPs.
The AI drug discovery company’s reorganization will include laying off around 180 employees and dropping its atopic dermatitis candidate BEN-2293 in an effort to save nearly $56 million.
The U.S. Food and Drug Administration on Thursday granted a full approval to Pfizer’s Paxlovid, an oral antiviral COVID-19 treatment for adults at high risk of progression to severe disease.
The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.
Brixadi’s extended-release feature distinguishes it from existing treatment options that typically require daily dosing. The drug also stands to improve patient adherence to treatment plans by eliminating the need for frequent administration, a common stumbling block.
The Dublin-based company also announced job cuts last month, with numbers undisclosed, while it is also looking to offload some of its smaller businesses such as patient monitoring and respiratory interventions to focus on its core units – heart and diabetes.
Germany’s BioNTech said it was on track to introduce a COVID-19 shot by the early fall in the northern hemisphere that is adapted to currently dominant virus variants in line with recommendations by the World Health Organization.